Publisher
Springer Science and Business Media LLC
Reference56 articles.
1. EMA, Vemlidy® 25 mg Film Coated Tablet, Assessment report, 2016. https://www.ema.europa.eu/en/documents/assessment-report/vemlidy-epar-public-assessment-report_en.pdf. Accessed 09 February 2024.
2. Avihingsanon A, Lu H, Leong CL, Hung CC, Koenig E, Kiertiburanakul S, Lee MP, Supparatpinyo K, Zhang F, Rahman S, D’Antoni ML, Wang H, Hindman JT, Martin H, Baeten JM, Li T. Bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir, emtricitabine, and tenofovir disoproxil fumarate for initial treatment of HIV-1 and hepatitis B coinfection (ALLIANCE): a double-blind, multicentre, randomised controlled, phase 3 non-inferiority trial. The Lancet HIV. 2023;10(10):640–52.
3. Boglione L, De Benedetto I, Dodaro V, Chiecchio M, De Nicolò A, Di Perri G, D’Avolio A. Role of plasmatic and urinary concentration of tenofovir disoproxil fumarate in a cohort of patients affected by chronic hepatitis B. Arch Virol. 2022;167(8):1669–74.
4. Chen CH, Jeng WJ, Hu TH, Liu YC, Wang JH, Cung CH, Lu SN, Chien RN. HBV relapse rates in patients who discontinue tenofovir disoproxil fumarate with or without switching to tenofovir alafenamide. Dig Liver Dis. 2023;55(6):771–7.
5. De Clercq E. Tenofovir alafenamide (TAF) as the successor of tenofovir disoproxil fumarate (TDF). Biochem Pharmacol. 2016;1(119):1–7.